Setbacks in Alzheimer research demand new strategies, not surrender

PLoS Medicine
Björn Jobkeas the PLOS Medicine Editors

Abstract

In this month's editorial, the PLOS Medicine Editors discuss the challenges of addressing a growing population with Alzheimer disease and dementia amidst disappointing news from the pharmaceutical industry.

References

Mar 23, 2012·Journal of Neuropathology and Experimental Neurology·Thomas G BeachWalter Kukull
Jan 24, 2014·The New England Journal of Medicine·Rachelle S DoodyUNKNOWN Solanezumab Study Group
Mar 19, 2016·Neuropathology : Official Journal of the Japanese Society of Neuropathology·Hiroyuki HondaToru Iwaki
Mar 9, 2017·Journal of Alzheimer's Disease : JAD·Mario F Mendez
Jan 25, 2018·The New England Journal of Medicine·Lawrence S HonigEric Siemers
Jan 31, 2018·PLoS Medicine·Anna Nordström, Peter Nordström

❮ Previous
Next ❯

Citations

Nov 18, 2018·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Richard S IsaacsonRobert Krikorian
Nov 5, 2019·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Richard S IsaacsonRobert Krikorian
Aug 26, 2020·Epidemiology·Venexia M WalkerPatrick G Kehoe
Apr 9, 2020·Frontiers in Pharmacology·Nurul Husna IbrahimJaya Kumar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Related Papers

Laboratory Animals
Beat Michael RiedererNathalie Baehler
PLoS Biology
Barbara Cohen
Psychiatria polska
Dominika DudekKatarzyna Klasa
© 2022 Meta ULC. All rights reserved